Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Shandong Boan Biotechnology Company., Limited. Class H ( (HK:6955) ).
Shandong Boan Biotechnology has announced a plan to repurchase its own shares on the open market, authorizing buybacks of up to HK$200 million under its existing and future shareholder-approved repurchase mandates. The company says it views its current trading price as undervaluing its intrinsic value and business prospects, and believes the program can support shareholder returns while preserving a solid financial position.
The board emphasizes that any repurchases will comply with Hong Kong listing rules, takeover and buy-back codes, and all relevant regulations, including restrictions around periods preceding results announcements. Repurchased shares may be cancelled, held in treasury, sold or transferred at the board’s discretion, and the company cautions investors that the timing, volume and pricing of any buybacks are not guaranteed and remain subject to market conditions.
More about Shandong Boan Biotechnology Company., Limited. Class H
Shandong Boan Biotechnology Co., Ltd. is a biopharmaceutical company listed in Hong Kong, operating in the biotechnology and pharmaceutical sector. It focuses on developing and commercializing innovative biologic drugs, with its shares traded under stock code 6955, and targets investors seeking exposure to China’s healthcare and biotech growth.
Average Trading Volume: 4,449,055
Technical Sentiment Signal: Sell
Current Market Cap: HK$3.87B
Find detailed analytics on 6955 stock on TipRanks’ Stock Analysis page.